Inspired by viral replication, researchers developed a therapy that commandeers biological processes to craft nanoparticles within macrophages to aid in cancer therapy. Through self-assembly, the nanoparticles address some of the delivery issues plaguing present renditions of nanomedicines, wherein nanomaterials are used to deliver drugs inside tissues.
Often, nanomedicines have a hard time reaching the right target, limiting their therapeutic impact and leading to side effects. Biological events can disrupt the targeted delivery of nanomedicines, and researchers are constantly working to improve their transport.
Nanosynth Group plc (LON:NNN) nano-technology business that originated in Nottingham from a partnership with Nottingham Trent University. Their core mission is to develop unique ways to produce and apply nanoparticles.